AlphaSense Expert Insights: Views Across the Channel

Research evidence excerpt

AlphaSense Expert Insights: Views Across the Channel

displacement of incumbents.

TXG (Associate Research Scientist at Yale and former Senior Scientist at NanoString). Expert

feedback highlights 10x maintaining a lead position but with elevated scrutiny around replacement

cycles and end-market exposure. 1) Atera. Driving clear excitement given the step-change in plex

(5k → 18k), albeit with some early-buyer backlash as researchers who recently installed Xenium

question obsolescence risk. 2) Spatial. Broadly expected to become mainstream over time, but

near-term adoption is gated by a lack of standardized analytics and workflow integration into clinical

pathology. Importantly, academic demand is constrained vs. pharma/clinical settings, which are

viewed as the primary path to scaling usage. 3) Data/AI. Companies are increasingly investing in

data/analytics and partnerships to enable clinical integration, positioning spatial as a next engine

of growth tied to big data and drug development if standardization is achieved.

Tycho Peterson * | Equity AnalystQGEN (former Sales Director). 1) Promega. Has emerged as a credible sample prep challenger,

+1 (212) 738-5583 | tpeterson2@jefferies.com

improving from lower-quality offerings to “good enough” products at 20-25% lower pricing, with an

Matthew Stanton * | Equity Analystestimated 10-15% share loss from QGEN to date (potential to reach 20-30%). 2) Pricing. Remains

(615) 963-8397 | mstanton@jefferies.com

the primary lever in a commoditizing sample prep market, with incumbents forced to discount

to defend share; labs are willing to switch for 20-25% savings (Promega) for semi-high-quality Priya Patel * | Equity Associate

+1 (332) 204-0140 | ppatel5@jefferies.com

products, while Chinese competitors can price at 50% discounts.